IN2012DN02876A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02876A
IN2012DN02876A IN2876DEN2012A IN2012DN02876A IN 2012DN02876 A IN2012DN02876 A IN 2012DN02876A IN 2876DEN2012 A IN2876DEN2012 A IN 2876DEN2012A IN 2012DN02876 A IN2012DN02876 A IN 2012DN02876A
Authority
IN
India
Prior art keywords
compounds
coupled receptor
protein coupled
modulate
modulating
Prior art date
Application number
Other languages
English (en)
Inventor
Yingzhi Bi
Carolyn Diane Dzierba
Joanne J Bronson
Kenneth Carson
Giovanni Cianchetta
Li Dong
Cynthia Fink
Michael Green
David Kimball
John E Macor
Soojin Kwon
Jiancheng Wang
Yulian Zhang
Greg Zipp
Original Assignee
Bristol Myers Squibb Co
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Lexicon Pharmaceuticals Inc filed Critical Bristol Myers Squibb Co
Publication of IN2012DN02876A publication Critical patent/IN2012DN02876A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN2876DEN2012 2009-10-07 2010-10-06 IN2012DN02876A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24946509P 2009-10-07 2009-10-07
PCT/US2010/051572 WO2011044195A1 (en) 2009-10-07 2010-10-06 Modulators of g protein-coupled receptor 88

Publications (1)

Publication Number Publication Date
IN2012DN02876A true IN2012DN02876A (enExample) 2015-07-24

Family

ID=43480829

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2876DEN2012 IN2012DN02876A (enExample) 2009-10-07 2010-10-06

Country Status (7)

Country Link
US (1) US8497271B2 (enExample)
EP (1) EP2486030B1 (enExample)
JP (1) JP2013507369A (enExample)
CN (1) CN102686575A (enExample)
ES (1) ES2428492T3 (enExample)
IN (1) IN2012DN02876A (enExample)
WO (1) WO2011044195A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
UA111746C2 (uk) * 2011-07-08 2016-06-10 Х. Луннбек А/С Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну
HRP20180913T1 (hr) 2011-07-08 2018-07-27 H. Lundbeck A/S Pozitivni alosterni modulatori receptora nikotinskog acetilkolina
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
WO2014006117A1 (en) * 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
HK1216095A1 (zh) * 2012-12-10 2016-10-14 H. Lundbeck A/S 烟碱乙酰胆碱受体的新的正向别构调节剂
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
CN113005089A (zh) * 2019-12-20 2021-06-22 泰州医药城国科化物生物医药科技有限公司 一种无标记细胞膜受体gpr88的细胞筛选模型及应用
CN111592531B (zh) * 2020-06-23 2023-08-15 上海鲲博玖瑞医药科技发展有限公司 福瑞塞替的制备方法
GB202209195D0 (en) 2022-06-22 2022-08-10 Pandeia Therapeutics Ltd Modulators of g protein-coupled receptor 88
GB202209193D0 (en) 2022-06-22 2022-08-10 Pandeia Therapeutics Ltd Modulators of g protein-coupled receptor 88

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ141795A3 (en) 1992-12-02 1995-11-15 Pfizer 4-substituted catechol diethers as such and for treating diseases and pharmaceutical preparations based thereon
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
CA2347092A1 (en) * 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
JP2005522489A (ja) 2002-04-05 2005-07-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆性インヒビターとして有用なシアナミド
WO2003103666A2 (en) 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
WO2004047738A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US7834013B2 (en) * 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
EP1773780A4 (en) 2004-06-24 2008-01-09 Incyte Corp AMIDO COMPOUNDS AND USES THEREOF AS PHARMACEUTICAL PRODUCTS
WO2006027252A1 (en) 2004-09-10 2006-03-16 Ucb Pharma, Sa Sigma receptor ligands
KR100927915B1 (ko) * 2005-03-17 2009-11-19 화이자 인코포레이티드 통증 치료에 유용한 n-(n-설폰일아미노메틸)사이클로프로판카복사마이드 유도체
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
MX2008012945A (es) 2006-04-07 2009-01-15 Vertex Pharma Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp).
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
US20080040819A1 (en) 2006-08-14 2008-02-14 Wyeth Methods of identifying agents for treatment of schizophrenia and related disorders
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88

Also Published As

Publication number Publication date
ES2428492T3 (es) 2013-11-08
US20110245264A1 (en) 2011-10-06
EP2486030B1 (en) 2013-07-24
EP2486030A1 (en) 2012-08-15
WO2011044195A1 (en) 2011-04-14
US8497271B2 (en) 2013-07-30
CN102686575A (zh) 2012-09-19
JP2013507369A (ja) 2013-03-04

Similar Documents

Publication Publication Date Title
IN2012DN02876A (enExample)
NZ612380A (en) Modulators of toll-like receptors
TN2010000062A1 (en) Pyrrolidin -2-one derivatives as androgen receptor modulator
MY172156A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12015501720A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12016501389A1 (en) S1p modulating agent
AU2011232516A8 (en) Chemical compounds
WO2007005887A3 (en) Androgen receptor modulator compounds, compositions and uses thereof
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
IN2012DN02580A (enExample)
MX2011008602A (es) Metodos de tratamiento de condiciones relacionadas con el cabello.
ZA201100014B (en) Piperazine derivatives used as cav2.2 calcium channel modulators
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
MX2009007336A (es) Indazoles substituidos con 5-furopiridinona.
WO2010057088A3 (en) Pyrrolidinyl modulators of nicotinic acetylcholine receptors
TN2013000201A1 (en) Methods and compositions for drying coal
MX2009010903A (es) Metodos para preparar compuestos basados en imidazol.
MY151180A (en) Electrocoating composition comprising a crater control additive
WO2009154739A3 (en) Smoothened receptor modulators
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
PH12013500819A1 (en) Tidal flow modulator
WO2010060070A3 (en) Indolinone modulators of dopamine receptor
PH12014500934A1 (en) Nicotinic receptor non-competitive modulators
UA101624C2 (ru) Производные пирролидин-2-она как модуляторы рецептора андрогена
UA49630U (ru) СОСТАВ Поверхностно-активнОГО вещества ДЛЯ ФОРМИРОВАНИЯ Износостойких Покрытий